Brad Calvin
MaxCyte has appointed Brad Calvin, a 25-year veteran within the drug development and biotechnology industries, as Executive Vice President of Global Marketing. In his role, Calvin is responsible for leading MaxCyte's marketing function to drive growth of the Company's drug discovery and cell therapy business.
"We are delighted to have someone of Brad's caliber join MaxCyte to lead our marketing and market development efforts. Brad's broad biopharmaceutical industry experience has provided him with an in-depth understanding of working across global markets and supporting all phases of product life cycles. His appointment comes at an opportune time for the Company, as we continue to develop new offerings based on our Flow Electroporation Technology," Doug Doerfler, Chief Executive Officer, said.
Calvin was most recently Co-founder and President of AsedaSciences, a company with an integrated technology platform to predict in vivo toxicity risk in early-stage drug discovery. Previously, he has held various leadership positions at companies ranging from large corporations to start-ups, such as Accuvein, Beckman Coulter, Qiagen, Digene, AGENIX, and Abbott Laboratories. He has a Bachelor's degree from Curtin Institute of Technology in Perth, Western Australia.